Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10441717 | 1.00 | SMO (0.73) | SMOGPR119 | |
| SCHEMBL4158731 | 1.00 | SMO (0.73) | SMOGPR119 | |
| SCHEMBL4162954 | 0.96 | SMO (0.73) | SMOGPR119 | |
| SCHEMBL3652380 | 0.96 | SMO (0.73) | SMOGPR119 | |
| SCHEMBL1102306 | 0.90 | SMO (0.70) | SMO | |
| SCHEMBL3639681 | 0.90 | SMO (0.70) | SMO | |
| SCHEMBL12371786 | 0.90 | SMO (0.70) | SMO | |
| SCHEMBL3645413 | 0.89 | SMO (0.73) | SMOGPR119 | |
| SCHEMBL3645410 | 0.89 | SMO (0.73) | SMOGPR119 | |
| SCHEMBL3697838 | 0.87 | SMO (0.83) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188283-B1 | ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING | AMGEN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8222251-B2 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222251-B2 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | DPYD, CYP3A5, PNPO | SMO 2449/4885GPR119 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.